Alzheimers Disease Clinical Trial
Official title:
A Phase 0, Open Label, Non-randomized, Multi-center Exploratory and Safety Study of [F-18]T807
Verified date | July 2013 |
Source | Avid Radiopharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
[F-18]T807 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.
Status | Terminated |
Enrollment | 11 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 55 Years and older |
Eligibility |
Inclusion Criteria; Low Probability for AD Participants (Group 1) - Participant has reached his or her 55th birthday at the time of informed consent (Participant is male or female of any race / ethnicity) - Participant provides written informed consent - Participant is capable of complying with study procedures - Participant is capable of communicating with study personnel - Participant understands and speaks English - Participant has at least an 8th Grade education - In the Investigator's opinion, participant has a low probability of being currently positive for AD as determined by a Mini Mental State Examination (MMSE = 28) defined in APPENDIX VI of protocol T807000, IND 114102 - Participant has no significant hepatic or renal disease as defined by previous medical history and lab results are within the following ranges: - Total bilirubin within 2x institutional upper limits of normal - AST (SGOT) = 2.5 x institutional upper limits of normal - ALT (SGPT) = 2.5 x institutional upper limits of normal - Creatinine = 2x institutional upper limits of normal - BUN within 2x institutional upper limits of normal High Probability for AD Participants (Group 2) - Participant has reached his or her 55th birthday at the time of informed consent (Participant is male or female of any race / ethnicity) - Participant or participant's legally acceptable representative provides written informed consent - Participant is capable of complying with study procedures - Participant is capable of communicating with study personnel - Participant understands and speaks English - Participant has at least an 8th Grade education - In the Investigator's opinion, participant has a high probability of being currently positive for AD that is determined by a Mini Mental State Examination (MMSE < 17) defined in APPENDIX VI of protocol T807000, IND 114102. - Participant has no significant hepatic or renal disease as defined by previous medical history, and lab results are within the following ranges: - Total bilirubin within 2x institutional upper limits of normal - AST (SGOT) = 2.5 x institutional upper limits of normal - ALT (SGPT) = 2.5 x institutional upper limits of normal - Creatinine = 2x institutional upper limits of normal - BUN within 2x institutional upper limits of normal Exclusion Criteria; All Participants - Female participant is pregnant or nursing - Participant has prior history of stroke or other condition of the head or neck that, in the Investigator's opinion, might affect circulation to the head or image interpretation - Participant has other neurodegenerative disease that is associated with cognitive impairment or dementia - Participant has a medical condition that might be associated with elevated amyloid levels, such as amyloid angiopathy, familial amyloidosis, chronic kidney dialysis, Down's syndrome - Participant has a history of significant cerebrovascular disease - Participant has previously received [F-18]T807 at any time - Participant has been involved in an investigative, radioactive research procedure within the past 14 days - Participant has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete data or data quality - Participant has a history in the last five years of significant prescription or non-prescription drug or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Irvine | California |
United States | Research Site | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Avid Radiopharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging | up to 15 days per patient | No | |
Primary | To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration | up to 15 days per patient | No | |
Primary | To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD | upto 15 days per patient | No | |
Primary | To assess the safety of IV administration of [F-18]T807 | Safety will be monitored for all subjects by the: Number of subjects experiencing adverse events from baseline to 24 hours post-administration. Number and type of adverse events. Changes in clinical laboratory assessments (CBC and clinical chemistry)from baseline to 24 hours post administration. Changes in physical examination from baseline to 24 hours post administration. Changes in vital sign measurements (systolic blood pressure [mmHg]; diastolic blood pressure [mmHg], pulse rate [bpm] and body temperature) from baseline prior to [F-18]T807 administration, at 60 +/- 15 minutes post administration, at the end of the final imaging session (approximately 100 minutes post administration)and at 24 hours post administration. Changes in ECG measurements, from baseline prior to [F-18]T807 administration, at 60 +/- 15 minutes post administration, at the end of the final imaging session (approximately 100 minutes post administration) and at 24 hours post administration. |
up to 24 hours post [F18]T807 administration | Yes |
Secondary | To begin collection of baseline [F-18]T807 PET/CT imaging data | The secondary endpoint of this investigational study is the collection of baseline whole body PET/CT images and PET/CT images of the brain, following administration of [F-18]T807 | up to 15 days per patient | No |
Secondary | To gain information to improve the study design for the conduct of future trials | The secondary endpoint of this investigational study is the collection of baseline whole body PET/CT images and PET/CT images of the brain, following administration of [F-18]T807 | up to 15 days per patient | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02409082 -
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
|
N/A | |
Terminated |
NCT02565511 -
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
Completed |
NCT01993836 -
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
|
Phase 4 | |
Terminated |
NCT05097131 -
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
|
||
Completed |
NCT00448799 -
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04639050 -
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT06424236 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05891496 -
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
|
Phase 3 | |
Terminated |
NCT01723488 -
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
|
Phase 0 | |
Completed |
NCT00911690 -
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
|
N/A | |
Recruiting |
NCT01479855 -
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
|
N/A | |
Completed |
NCT01469351 -
Identifying Potential Effects of Liraglutide on Degenerative Changes
|
N/A | |
Completed |
NCT00439010 -
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05269394 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
|
Phase 2/Phase 3 | |
Recruiting |
NCT01760005 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
|
Phase 2/Phase 3 | |
Completed |
NCT04623242 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
|
Phase 2/Phase 3 | |
Suspended |
NCT05552157 -
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
Completed |
NCT04023994 -
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
|
Phase 1 | |
Terminated |
NCT03131453 -
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
Completed |
NCT01946243 -
The Feasibility of Florbetapir Quantitation
|
Phase 4 |